Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

3.2K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.2K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

10.3K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
Experimental RNAi02:15

Experimental RNAi

8.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

741
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
741
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

24
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>NRAS</i> mRNA-Degrading Bifunctional Small Molecules Induce Diverse Cellular Morphological Changes in Cancer Cells.

JACS Au·2026
Same author

Pyrazolylpyrimidinamines Decorated via Petasis Reaction as Small-Molecule Activators of the RNA-Degrading Ribonuclease IRE1α.

ACS bio & med chem Au·2026
Same author

Harnessing indole scaffolds to identify small-molecule IRE1α inhibitors modulating XBP1 mRNA splicing.

Nature communications·2025
Same author

Identification of 5-amino-1,3,4-thiadiazole appended isatins as bioactive small molecules with polypharmacological activities.

RSC medicinal chemistry·2025
Same author

Aminothiazolone Inhibitors Disrupt the Protein-RNA Interaction of METTL16 and Modulate the m<sup>6</sup>A RNA Modification.

JACS Au·2024
Same author

<i>N</i>-Biphenyl Pyrrolinones and Dibenzofurans as RNA-Binding Protein LIN28 Inhibitors Disrupting the LIN28-<i>Let-7</i> Interaction.

ACS medicinal chemistry letters·2023

Related Experiment Video

Updated: Mar 30, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Recent Advances in Small-Molecule Modulators Targeting IRE1α.

Yang Liu1,2, Peng Wu3,2

  • 1Department of Chemical Biology, Max Planck Institute of Molecular Physiology, Dortmund, Germany. yang.liu@mpi-dortmund.mpg.de.

Chimia
|March 28, 2026
PubMed
Summary

Small molecules targeting IRE1α (inositol-requiring enzyme 1 alpha) show promise for treating diseases by modulating its kinase and ribonuclease activity. Recent advances include inhibitors, activators, and degraders for therapeutic development.

Keywords:
Allosteric inhibitorsPROTACRNA splicingRibonuclease and IRE1αSmall-molecule modulators

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
11:58

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

8.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
11:58

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

8.8K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Inositol-requiring enzyme 1 alpha (IRE1α) is a key endoplasmic reticulum (ER) stress sensor with dual kinase and ribonuclease functions.
  • IRE1α is critical for maintaining ER proteostasis and its dysregulation is implicated in various human diseases.
  • Targeting IRE1α represents a promising therapeutic strategy.

Purpose of the Study:

  • To review recent advancements in small molecule modulators of IRE1α.
  • To provide insights into the mechanisms of IRE1α modulation.
  • To discuss the future development of chemical modalities targeting IRE1α.

Main Methods:

  • Summary of recent literature on IRE1α inhibitors, activators, and bifunctional molecules.
  • Analysis of small molecule binding sites (RNase and kinase domains).
  • Review of proteolysis targeting chimeras (PROTACs) for IRE1α degradation.

Main Results:

  • Small molecules can modulate IRE1α RNase activity by directly inhibiting the RNase domain or allosterically via the kinase domain.
  • Various monovalent inhibitors and activators have been identified.
  • PROTACs offer a strategy to degrade IRE1α via the ubiquitin-proteasome system.

Conclusions:

  • Small molecule targeting of IRE1α is a rapidly advancing field with significant therapeutic potential.
  • Diverse chemical modalities, including inhibitors, activators, and degraders, are being developed.
  • Further research into these chemical strategies may lead to novel treatments for IRE1α-associated diseases.